Maintenance therapy with pemetrexed foradvanced non-small cell lung cancer:A Meta-analysis of RCTs
10.11904/j.issn.1002-3070.2016.01.006
- VernacularTitle:培美曲塞维持治疗晚期非小细胞肺癌临床疗效的Meta分析
- Author:
Long CHENG
;
Jianguo ZHOU
;
Hang ZHOU
- Publication Type:Journal Article
- Keywords:
Pemetrexed;
Non-small cell lung cancer;
Maintenance therapy;
Meta-analysis
- From:
Practical Oncology Journal
2016;30(1):28-35
- CountryChina
- Language:Chinese
-
Abstract:
Objective This paper aims to assess the clinical efficacy of pemetrexed maintenance therapy in patients with advanced non-small cell lung cancer( NSCLC) through Meta analysis.Me thods Systematic lit-erature searches were performed in Cochrane、Pubmed,Web of science, Embase and ClinicalTrials databases.The related references had been traced.We made quality assessment of qualified randomized controlled trials( RCTs) of pemetrexed maintenance therapy compared with best supportive care( BSC) in advanced NSCLC.Besides,we u-tilized stata 12.0,Revman 5.3 and GRADEpro software to evaluate the overall quality of the evidence,according to the Cochrane collaboration to perform Meta-analysis.Resutl s Three RCTs were eligible and included 1257 patients.Meta-analysis results suggested that:compared to BSC,pemetrexed maintenance therapy had a statisti-cally significant benefit in improving progression-free survival(PFS)(HR =0.55,95% CI:0.48~0.64)and overall survival(HR=0.76,95%CI:0.65~0.88).The objective response(ORR)did not reach statistical signif-icance(RR=0.97,95%CI:0.86~1.10).Conclusion Compared with BSC,pemetrexed maintenance therapy statistically significantly improve PFS and OS,but has no demonstrable impact on ORR in patients with advanced NSCLC.
